Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$183.78 USD

183.78
973,427

-0.44 (-0.24%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $183.78 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (150 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Urmimala Biswas headshot

Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?

by Urmimala Biswas

Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.

Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ResMed (RMD) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for ResMed (RMD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Indrajit Bandyopadhyay headshot

5 Medical Product Stocks to Buy Amid Industry Challenges

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, RMD, ZBH, PODD and LNTH are well-poised to gain from the favorable factors.

Here's Why Investors Should Buy ResMed (RMD) Stock Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) led by the strong uptake of the myAir app with Air 11 systems.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

ResMed (RMD) Debuts the Smallest Full-Face CPAP Mask AirFit F40

by Zacks Equity Research

ResMed's (RMD) new AirFit F40 mask combines the ease and comfort of an ultra-compact, full-face mask with the effectiveness of a traditional over-the-nose, full-face mask.

Why Is ResMed (RMD) Down 1.7% Since Last Earnings Report?

by Zacks Equity Research

ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed's (RMD) increased adoption of AirSense10 and AirSense11 devices.

ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 (Revised)

by Zacks Equity Research

ResMed's (RMD) new AirCurve11 series incorporates MyAir and AirView digital health apps to provide maximum comfort and support during therapy.

ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 Device

by Zacks Equity Research

ResMed's (RMD) new AirCurve11 series incorporates myAir and AirView digital health apps to provide maximum comfort and support during therapy.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why ResMed (RMD) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

ResMed's (RMD) Q2 results reflect cost discipline to support an acceleration in profitability.

ResMed (RMD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

ResMed (RMD) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

ResMed (RMD) delivered earnings and revenue surprises of 3.87% and 0.46%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Stay Ahead of the Game With ResMed (RMD) Q2 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Evaluate the expected performance of ResMed (RMD) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) on strong uptake of the myAir app with AirSense11.

Here's Why ResMed (RMD) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD) due to the sustained growth in the SaaS business.

Why ResMed (RMD) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Envista (NVST) Up 6.8% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Envista (NVST) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.